CHCHD4

Mutation & survival
SurvivalMutationKaplan–Meier · TCGA cohorts

Across TCGA pan-cancer cohorts, CHCHD4 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CHCHD4 data layer compared with 22 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher CHCHD4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CHCHD4 expression acts as an unfavorable survival marker.

SKCM, LIHC, and ESCA are the cancer types where CHCHD4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.
LineageMeasureSplitStageAUC1
high
AUC2
low
pSampling consensus
SKCMOSMedianAll0.2590.789<.00118view →
LIHCOSMedianII,III,IV0.0940.696<.00112view →
ESCAOSMedianII,III,IV0.2160.702.0146view →
UCECOSMedianIV0.2310.592.0366view →
Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CHCHD4–SKCM (OS)

Kaplan–Meier survival curve for CHCHD4 mutant vs wild-type samples in SKCM.

Open the SKCM breakdown →

Exploration